Adrabetadex (Mandos/National Institutes of Health)

羟丙基倍他环糊精 (Mandos/National Institutes of Health)

Report date: 2026/05/09 20:00:18

Base Information

Drug NameAdrabetadex (Mandos/National Institutes of Health)
Drug Alias Name羟丙基-β-环糊精HPBCDTrappsol HPB羟丙基-beta-环糊精2-HP-beta-CD +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCholesterol modulatorsBinding agents
TargetsCholesterol
Therapy Area/IndicationsWounds and InjuriesPressure UlcerAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeSweden +[19] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of HealthMando's Llc
China Registration ClassN/A

Develop Information

Active CompaniesRafael Holdings IncWashington University School Of MedicineCyclo Therapeutics Inc +[4] 
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentVtesse IncState University Of Maringa
Active IndicationsAlzheimer DiseaseNiemann-Pick Disease, Type C
Inactive IndicationsWounds and InjuriesPressure Ulcer

Other Information

ATC CodeN/A
Related LinksDrugBank